Welcome, visitor! [ Login

全球制药业并购 2011 Pharmaceutical M&A deals in 2011

Medical Blog 2012-07-14

 

Pharmaceutical M&A deals in 2011

Details for the 129 M&A announcements recorded by The Pharma Letter are provided in the full table below:
Compared with 117 in 2010, which was then a record number (Pharmaceutical M&A deals in 2010, The Pharma Letter January 13, 2011).

 

Company

  

Takeover candidate

  

 

Deal Value US $ *

  

 

Completed

  

 

Abcam (UK) 

 

MitoSciences (UK) 

 

Undisclosed 

 

May-11 

 

Abcam (UK) 

 

Ascent Scientific (UK) 

 

$15.9 million 

 

Sep-11 

 

Acino Pharma (Switz) 

 

Mepha (Switz) MENA, Latin America and Asia business units from Teva subsidiary Cephalon 

 

$226.0 million 

 

Dec-11 

 

ADVENTRX Pharma (US) 

 

SynthRx (US) 

 

Undisclosed stock deal 

 

Apr-11 

 

Affymetrix (US) 

 

eBioscience (US) 

 

$330.0 million 

 

Dec-11 

 

Alere (US) 

 

Axis-Shield (UK) 

 

$365.0 million 

 

Bid announced July; Alere went hostile Aug 5; closed Nov 2011 

 

Alexion Pharma (US) 

 

Taligen Therapeutics (US) 

 

$111.0 million 

 

Feb-11 

 

Alexion Pharma (US) 

 

Enobia Pharma (Canada) 

 

$610.0 million upfront and $470 million contingent on regulatory milestones 

 

Exp 1st-qtr 2012 

 

Alkermes (US) 

 

Elan Drug Technologies unit of Elan Corp (Ireland) 

 

$960 million cash and stock deal 

 

Sep-11 

 

Allergan (US) 

 

Vicept Thera (US) 

 

$275.0 million, of which $75 mill upfront 

 

Jul-11 

 

Allozyne (US) 

 

Poniard Pharma (US) 

 

Stock exchange deal 

 

Announced June 23. Deal called off Dec 2011 

 

Amgen (US) 

 

BioVex (US)   

 

$1.0 billion. Paid $435 million upfront with further $575 million in milestones 

 

Mar-11 

 

Amgen (US) 

 

Bergamo (Brazil) 

 

$215.0 million 

 

Apr-11 

 

Ancient Pharma (US) 

 

Timm Medical (US) 

 

Undisclosed 

 

Jan-11 

 

Apricus Biosciences (US) 

 

US subsidiary of Topotarget A/S (Denmark) 

 

$2.0 million plus $2 million stock based on milestones 

 

Dec-11 

 

Asahi Kasei Pharma (Japan) 

 

Artisan Pharma (US) 

 

Undisclosed 

 

Nov-11 

 

Astellas (Japan) 

 

Perseid Therapeutics (US) Buys Maxygen’s stake in JV 

 

$76.0 million 

 

May-11 

 

AstraZeneca (UK) 

 

Guangdong BeiKang Pharma (China) 

 

Undisclosed 

 

Exp 1st-qtr 2012 

 

Axcan (Canada) 

 

Mpex (US) 

 

$230.0 million 

 

Nov-11 

 

Baxter Int (US) 

 

Prism Pharma (US) 

 

$388.0 million of which $170 million upfront 

 

June 2-011 

 

Baxter Int (US) 

 

Baxo Corp (US) 

 

$380.0 million 

 

Nov-11 

 

Baxter Int (US) 

 

Synovis Life Technologies (US) 

 

$325.0 million 

 

Exp 1st-qtr 2012 

 

Biostar Pharma (US) 

 

Shaanxi Weinan (China) 

 

$9.6 million stock deal 

 

Oct-11 

 

Biotie Thera (Finland) 

 

Synosia Thera (Switz) 

 

$121.5 million 

 

Feb-11 

 

Biotie Thera (Finland) 

 

Newron Pharma (Italy) 

 

$60.8 million 

 

Deal cancelled 

 

BioTime (US) 

 

Glycosan Bio Systems (US) 

 

Undisclosed stock deal 

 

Mar-11 

 

BioTime (US) 

 

Cell Targeting (US) 

 

Undisclosed stock deal 

 

Jan-11 

 

Bluefish Pharma (Sweden) 

 

BMM Pharma unit of Medivir (Sweden) 

 

$6.0 million 

 

Aug-11 

 

Bristol-Myers Squibb (US) 

 

Amira Pharma (US) 

 

$325.0 million plus $150.0 million milestones 

 

Sep-11 

 

Celesio (Germany) 

 

OncoProd (Brazil) 60% stake 

 

Undisclosed 

 

Oct-11 

 

Cephalon (US) 

 

Gemin X Pharma (US) 

 

$225.0 million plus milestones of up to $300 million 

 

2011 

 

Cephalon (US) 

 

ChemGenex (Australia) 

 

$231.0 million 

 

2011 

 

Cornerstone Therapeutics (US) 

 

Cardiokine (US) 

 

Undisclosed 

 

Dec-11 

 

Cubist Pharma (US) 

 

Adolor Corp (US) 

 

$221 upfront plus contingent payment right worth up to $225 million 

 

Dec-11 

 

Cynapsus Therapeutics (Canada) 

 

Adagio Pharma (Canada) 

 

$5.55 million 

 

Dec-11 

 

Daiichi Sankyo (Japan) 

 

Plexxikon (US) 

 

$805.0 million 

 

Apr-11 

 

Elan (Ireland) 

 

Proteostasis Therapeutics (US) 

 

$20.0 million for 24% equity stake 

 

May-11 

 

Endo Pharma (US) 

 

American Medical Systems (US) 

 

$2.9 billion 

 

Jun-11 

 

Evotec (Germany) 

 

Kinaxo (Germany) 

 

$17 million 

 

Apr-11 

 

Ewopharma (Swiss) 

 

Newport Pharma subsid of Immdal (Ireland) 

 

Undisclosed 

 

Oct-11 

 

Farmsintez (Russia) 

 

Kevelt (Estonia) 

 

Undisclosed 

 

Jan-11 

 

Ferring Pharma (Swiss) 

 

Cytokine PharmaSciences (US) 

 

Undisclosed 

 

Oct-11 

 

Footstar (US) 

 

CPEX Pharma (US) 

 

$76.6 million 

 

Apr-11 

 

Forest Labs (US) 

 

Clinical Data (US) 

 

$1.2 billion 

 

Apr-11 

 

Fosun Pharma (China) 

 

Aleph Biomed (China) 75% stake 

 

$102.0 million 

 

Feb-11 

 

Galenica (Switz) 

 

Vifor Uriach, the joint venture with Grupo Uriach (Spain) 

 

Undisclosed 

 

Nov-11 

 

Gilead Sciences (US) 

 

Calistoga Pharma (US) 

 

$375.0 million plus possible $225 million in milestones 

 

Apr-11 

 

Gilead Sciences (US) 

 

Pharmasset (US) 

 

$11.0 billion 

 

Exp 1st-qtr 2011 

 

Grifols (Spain) 

 

Talecris Biotherapeutics (US) 

 

$3.4 billion 

 

Jun-11 

 

Hikma Pharma (Jordan) 

 

Unimark Remedies (India) – 25% stake 

 

$33.3 million 

 

May-11 

 

Hikma Pharma (Jordan) 

 

Baxter injectable generics business 

 

$112.0 million (First announced in 2010) 

 

May-11 

 

Hikma Pharma (Jordan) 

 

Hubei Haosun (China) minority stake 

 

$5.0 million 

 

2011 

 

Hikma Pharma (Jordan) 

 

Promopharm (Morocco) 

 

$111.2 million for 63.9% stake; intends to buy remainder 

 

Due end Jan 2012 

 

Histogenics (US) 

 

ProChon Biotech (Israel) 

 

Undisclosed stock-for-stock deal 

 

May-11 

 

Intrexon (US) 

 

Immunologix (US) 

 

Undisclosed 

 

Oct-11 

 

IS Pharma (UK) 

 

Helsinn Healthcare (Switz) Helsinn Birex unit in Ireland 

 

$6.0 million 

 

Feb-11 

 

Jazz Pharma (US) 

 

Azur Pharma (Irish) 

 

All stock merger with Jazz shareholders owning nearly 80%  

 

Dec-11 

 

Johnson & Johnson (US) 

 

Synthes (Switz) 

 

$21.3 billion 

 

EU Commission launched investigation Nov 2011, decision due Apr 2012 

 

Johnson & Johnson (US) 

 

J&J-Merck Consumer (US). Buys Merck & Co’s 50% stake in JV 

 

$175.0 million 

 

Sep-11 

 

Kyowa Hakko Kirin (Japan) 

 

ProStrakan (UK) 

 

$474.3 million 

 

Apr-11 

 

Kohlberg Kravis Roberts (US) 

 

Capsugel (US) a unit of Pfizer 

 

$2.38 billion 

 

Aug-11 

 

Ligand Pharma (US) 

 

CyDEX Pharma (US) 

 

$31.2 million, plus contingent payments 

 

Jan-11 

 

Eli Lilly (US) Elanco unit 

 

Janssen Pharma animal health business 

 

Undisclosed 

 

Jul-11 

 

Lupin (India) 

 

I’rom Pharma unit of I’rom Holdings (Japan) 

 

Undisclosed 

 

Nov-11 

 

Medicis (US) 

 

Graceway Pharma (US) 

 

$455.0 million 

 

Dec-11 

 

Medivir (Sweden) 

 

BioPhausia (Sweden) 

 

$90.8 million 

 

Jun-11 

 

Merck & Co (US) 

 

Inspire Pharma (US) 

 

$430.0 million 

 

May-11 

 

Merck KGaA (Germany) 

 

Beijing Skywing (China) 

 

$18.2 million 

 

Jan-11 

 

Merck KGaA (Germany) 

 

Microbiology business of Biotest AG (Germany) 

 

Undisclosed 

 

Aug-11 

 

Menarini (Italy) 

 

Invida (Singapore) 

 

Undisclosed) 

 

Nov-11 

 

Mitsui & Co (Japan) 

 

Mercian (Japan) pharma and chemical business 

 

Undisclosed 

 

Jun-11 

 

NeoStem (US) 

 

Progenitor Cell Therapy (US) 

 

About $20.0 million 

 

Oct-11 

 

Nitto Denko (Japan) 

 

Avecia Biotech (US) 

 

Undisclosed 

 

Feb-11 

 

Novartis (Switz) 

 

Genoptix (US) 

 

$470.0 million 

 

Jun-11 

 

Novartis (Switz) 

 

Zhejiang Tianyuan (China) – 85% stake 

 

$125.0 million 

 

Mar-11 

 

Novelos Thera (US) 

 

Cellectar (US) 

 

Stock deal 

 

Apr-11 

 

Nycomed (Switz) 

 

Lab Farmacol (Colombia) 

 

Undisclosed 

 

Jun-11 

 

OPKO Health (US) – controlled by Teva 

 

FineTech Pharmaceutical (Israel) 

 

$27.5 million 

 

Dec-11 

 

Paladin Labs (Canada) 

 

Labopharm (Canada) 

 

$20.6 million 

 

Oct-11 

 

Par Pharmaceutical (US) 

 

Edict Pharmaceuticals (India) 

 

$37.6 million plus assumption of debt 

 

Nov-11 

 

Par Pharma (US) 

 

Anchen Pharma (US) 

 

$410.0 million 

 

Nov-11 

 

Perrigo (US) 

 

Paddock Labs (US) 

 

$540.0 million 

 

Jul-11 

 

Pfizer (US) 

 

Ferrosan (Denmark) Consumer health unit 

 

Undisclosed 

 

Dec-11 

 

Pfizer (US) 

 

Icagen (US) 

 

$56.0 million enterprise value 

 

Oct-11 

 

Pfizer (US) 

 

Excaliard Pharma (US) 

 

Undisclosed 

 

Dec-11 

 

Pharmstandard (Russia) 

 

PJSC Biolek (Russia) 

 

Undisclosed 

 

Jan-11 

 

Qiagen (Netherlands) 

 

Cellestis (Australia) 

 

$355.0 million 

 

Sep-11 

 

Qiagen (Netherlands) 

 

Ipsogen (France) 

 

$101.0 million 

 

Jul-11 

 

Recordati (Italy) 

 

Frik Ilac (Turkey) 

 

$130 million 

 

Sep-11 

 

Repligen (US) 

 

Novozymes Biopharma Sweden unit of Denmark’s Novozymes 

 

$22.7 upfront and $5.6 million milestones 

 

Dec-11 

 

Roche (Swiss) 

 

PVT Probenverteiltecknik (Germany) 

 

$90.0 million, plus performance-related milestone 

 

May-11 

 

Roche (Swiss) 

 

mtm laboratories (Germany) 

 

$268.4 million 

 

Aug-11 

 

Roche (Swiss) 

 

Anadys Pharma (US) 

 

$230.0 million 

 

Nov-11 

 

Rxi Pharma (US) 

 

Apthera (US) 

 

$7.2 million plus milestones 

 

Apr-11 

 

Salix Pharma (US) 

 

Oceana Therapeutics (US) 

 

$300.0 million 

 

Dec-11 

 

Sanofi (France) 

 

Genzyme (US) 

 

$21.1 billion plus CVR 

 

Apr-11 

 

Sanofi (France) 

 

OTC business of Universal Medicare (India) 

 

$100 million (Est) 

 

Nov-11 

 

Santen Pharma (Japan) 

 

Novagali (France) 

 

50.55% stake with aim of buying remained for around $135 million 

 

First tranche completed Oct 2011 

 

SciClone Pharma (US) 

 

NovaMed Pharma (China) 

 

$104.8 million cash and shares, with $61.8 upfront 

 

Apr-11 

 

Shire (Ireland) 

 

Advanced BioHealing (US) 

 

$750.0 million 

 

Jun-11 

 

Sinclair IS (UK) 

 

Advanced Bio-Technologies (US) 

 

$32.8 million 

 

Ann Dec 8, close exp 1st-qtr 2011 

 

Sinclair Pharma (UK) 

 

IS Pharma (UK) 

 

Est $208 million stock deal merger 

 

2011 

 

SOHM (US) 

 

Novatrend Medicament (India) 

 

Undisclosed 

 

Nov-11 

 

STADA Arzneimittel (Germany) 

 

Generics business of Spirig Pharma (Switz) 

 

$109.2 million 

 

Exp 1st-qtr 2012 

 

Sucampo Pharma (US) 

 

Sucampo AG (Switz) and Sucampo AG Japan (Japan) 

 

$80.0 million 

 

Jan-11 

 

Sun Pharma (India) 

 

Caraco Pharma (US) Remaining 24.2% shares 

 

$5.25/share 

 

Jun-11 

 

SuperGen (US) 

 

Astex Therapeutics (UK) 

 

$25.0 million plus $30 million deferred 

 

Jul-11 

 

Synageva BioPharma (US) 

 

Trimeris (US) 

 

All stock deal for Trimeris which has market cap of $63.6M 

 

Jul-11 

 

Takeda (Japan) 

 

Fate Therapeutics (US) Unspecified stake 

 

Undisclosed 

 

May-11 

 

Takeda (Japan) 

 

Nycomed (Switz) 

 

$13.68 billion 

 

Sep-11 

 

Takeda (Japan) 

 

Intellikine (US) 

 

$190.0 million up front plus $120 million in contingent milestones 

 

Exp Jan 2012 

 

Teva Pharma Industries (Israel) 

 

Infarmasa (Peru) 

 

Undisclosed 

 

Jan-11 

 

Teva Pharma Industries (Israel) 

 

Cephalon (US) 

 

$6.8 billion 

 

Oct-11 

 

Teva (Israel) 

 

Taiyo Pharma (Japan) 100% stake 

 

$934.0 million 

 

Jul-11 

 

Teva (Israel) 

 

CureTech (Israel) increases equity stake to 75% 

 

$19.0 million plus $50 million R&D funding 

 

Oct-11 

 

Teva (Israel) 

 

Teva-Kowa-Pharma, a joint venture with Kowa (Japan) 

 

$150.0 million for Kowa’s 50% share 

 

Oct-11 

 

The Medicines Company (US) 

 

GeNO (US) undisclosed non-majority stake 

 

Undisclosed 

 

Dec-11 

 

Valeant Pharma (Canada) 

 

PharmaSwiss (Switz) 

 

$480.0 million 

 

Mar-11 

 

Valeant Pharma (Canada) 

 

Sanitas (Lithuania) 

 

$444.4 million 

 

Aug-11 

 

Valeant (Canada) 

 

Dermik (Canada & US) subsidiary of Sanofi (France) 

 

$422.5 million 

 

Dec-11 

 

Valeant (Canada) 

 

Ortho Dermatologics (unit of Johnson & Johnson)  

 

$345.0 million 

 

Ann july; FTC appro gained Dec 12 2011 

 

Valeant (Canada) 

 

Afexa Life Sciences (Canada) 

 

$76.9 million 

 

Completed Dec 2011. Ann. Aug 31 in Battle with Paladin for control 

 

Valeant (Canada) 

 

iNova (Australia) 

 

$703.8 million (including A$75 million contingent payment 

 

Dec-11 

 

Valeant (Canada) 

 

ISTA Pharma (US) 

 

$327.0 million 

 

Ann Nov but rejected, and Valeant went hostile Dec 2011 

 

ViroPharma (US) 

 

DuoCort Pharma (Sweden) 

 

$164.0 million 

 

Nov-11 

 

Watson Pharma (US) 

 

Specifar Pharma (Greece) 

 

$562.0 million plus 400 million-euro contingent 

 

May-11 

 

XTL Biopharma (Israel) 

 

MinoGuard (Israel) technology 

 

Undisclosed 

 

Nov-11 

 

Zydus Cadila (India) 

 

Nesher Pharma generics unit of K-V Pharmaceutical US) 

 

$60.0 million 

 

Aug-11 

 

Zydus Cadila (India) 

 

Biochem (India) 

 

Undisclosed 

 

Dec-11 

 

 

* Where not announced in US dollars, transaction values are calculated at the exchange rates prevailing at the time of announcement.

4652 total views, 0 today

200 PHARMACEUTICAL COMPANIES

Medical Blog 2012-07-06

 

200 PHARMACEUTICAL COMPANIES

Below are direct links to approximately 200 pharmaceutical companies

3 M Pharmaceuticals
www.3m.com

Abbott Laboratories
www.abbott.com

Alcon
www.alconlabs.com

Allergan
www.allergan.com

Alpha Therapeutic Corporation
www.alphather.com

Alpharma
www.alpharma.com

AltiMed Pharmaceutical Company
www.altimed.com

ALZA Corp.
www.alza.com

American Home Products Corporation (Wyeth)
www.ahp.com

AMGEN
www.amgen.com

Amylin
www.amylin.com

Apothecus
www.apotehcus.com

AstraZeneca
www.astrazeneca.com

Atrix Laboratories, Inc.
www.atrixlabs.com

Avant Immunotherapeutics
www.avantimmune.com

Aventis
www.aventis.com

Aviron
www.aviron.com

Barr Laboratories, Inc (US)
www.barrlabs.com

Bausch & Lomb
www.bausch.com

Bayer
www.bayerpharma.com

Baxter International Inc
www.baxter.com

Berlex Laboratories
www.berlex.com

Bertek Pharmaceuticals
www.bertek.com

Biogen, Inc
www.biogen.com

Bioglan
www.bioglan.com

Boehringer Ingelheim
www.boehringer-ingelheim.com

Bristol-Myers Squibb
www.bms.com

Centocor
www.centocor.com

Cephalon, Inc
www.cephalon.com

Chiron
www.chiron.com

Ciba (Novartis)
www.cibasc.com

CollaGenex Pharmaceuticals, Inc
www.collagenex.com

ConvaTec
www.convatec.com

COR Therapeutics, Inc
www.corr.com

Cortecs plc (Provalis)
www.cortecs.com

Coulter Pharmaceuticals
www.coulterpharm.com

Covance, Inc
www.covance.com

Curis Pharmaceuticals
www.curis.com

CP Pharmaceuticals
www.cppharma.com

Cytogen Corporation
www.cytogen.com

Daiichi Pharmaceutical Corp.
www.daiichius.com

Dermik Laboratories, Inc
www.dermik.com

Dey Laboratories
www.deyinc.com

DJ Pharma, Inc
www.djpharma.com

Dura Pharmaceuticals (US)
www.durapharm.com

Dupont Pharmaceuticals Company
www.dupontpharma.com

Duramed Pharmaceuticals
www.duramed.com

ECR Pharmaceuticals
www.ecrpharmaceuticals.com

Eisai Inc (US)
www.eisai.com

Elan Corporation
www.elancorp.com

Eli Lilly & Company
www.lilly.com

Endo Pharmaceuticals (US)
www.endo.com

EntreMed
www.entremed.com

Enzon, Inc
www.enzon.com

Ethicon
www.ethiconinc.com

Everett Laboratories
www.everettlabs.com

Ferndale Laboratories
www.ferndalelabs.com

Ferring Pharmaceuticals
www.ferringusa.com

Fleming & Company
www.flemingcompany.com

Forest Laboratories
www.frx.com

Fujisawa Pharmaceutical Co., Ltd.
www.fujisawa.com

Galderma Laboratories, Inc
www.galderma.com

Gate Pharmaceuticals (US)
www.gatepharma.com

GelTex Pharmaceuticals
www.geltex.com

Genentech, Inc
www.gene.com

Genzyme Corporation
www.genzyme.com

Gilead Sciences
www.gilead.com

Guilford Pharmaceuticals
www.guilfordpharm.com

Gynetics, Inc
www.gynetics.com

ICN Pharmaceuticals
www.icnpharm.com

IDEC Pharmaceuticals Corporation
www.idecpharm.com

Immunex Corporation
www.immunex.com

Incyte Pharmaceuticals
www.incyte.com

Innovex (Quintiles)
www.innovexglobal.com

Interferon Sciences, Inc
www.interferonsciences.com

InterMune Pharmaceuticals
www.intermune.com

Janssen Pharmaceutica
www.janssen.com

Johnson & Johnson
www.jnj.com

Jones Pharm (US)
www.jmedpharma.com

King Pharmaceuticals
www.kingpharm.com

Knoll Pharmaceutical Company
www.knoll-pharma.com

Kos Pharmaceuticals, Inc.
www.kospharm.com

Kramer Laboratories
www.kramerlabs.com

KV Pharmaceuticals
www.kvpharma.com

LaJolla Pharmaceuticals
www.ljpc.com

Lee Pharmaceuticals
www.leepharmaceuticals.com

Ligand Pharmaceuticals
www.ligand.com

LigoCyte Pharmaceuticals, Inc.
www.ligocyte.com

Liposome Company, Inc
www.lipo.com

Lotus Biochemical Corporation
www.lotusbiochemical.com

Mallinckrodt
www.mallinckrodt.com

Matrix Pharmaceuticals
www.matrix.com

Maxim Pharmaceuticals
www.maxim.com

Medicis Pharmaceutical Corp.
www.medicis.com

MedImmune
www.medimmune.com

Merck & Co.
www.merck.com

MGI Pharma Inc
www.mgipharma.com

Microcide Pharmaceuticals
www.microcide.com

Mission Pharmacal Company
www.missionpharmacal.com

Monarch Pharmaceuticals
www.monarchpharm.com

Muro Pharmaceutical
www.muropharm.com

Mylan Laboratories (US)
www.mylan.com

NeoTherapeutics, Inc
www.neotherapeutics.com

Neurogen
www.neurogen.com

Nexell Therapeutics
www.nexellinc.com

Novartis Pharmaceuticals Worldwide
www.novartis-us-pharma.com

Novo Nordisk
www.novonordisk.com

NPS Pharmaceuticals, Inc
www.npsp.com

Nutromax Laboratories
www.nutramaxlabs.com

Onyx Pharmaceuticals
www.onyx-pharm.com

Organon
www.organon.com

Ortho-McNeil Pharmaceuticals
www.ortho-mcneil.com

OSI Pharmaceuticals, Inc.
www.osip.com

Otsuka America Pharmaceuticals, Inc.
www.otsuka.com

Oxford-GlycoSciences
www.ogs.com

Paddock Laboratories
www.paddocklabs.com

Pan American Laboratories
www.panamericanlabs.com

PathoGenesis Corp.
www.pathogenesis.com

Pedinol Pharmacol, Inc
www.pedinol.com

Penwest Pharmaceuticals Co.
www.penw.com

Peptech Limited
www.peptech.com

Perrigo
www.perrigo.com

Pfizer
www.pfizer.com

Pharmacia
www.pharmacia.com
(see also
www.pfizer.com)

Pharmanetics
www.pharmanetics.com

Proctor & Gamble Company
www.pgpharma.com

Procyte
www.procyte.com

Professional Detailing
www.pdi-inc.com

Progenics Pharmaceuticals
www.progenics.com

Ross Products
www.ross.com

Questcor Pharmaceuticals
www.questcor.com

Quintiles Transnational Corp.
www.quintiles.com

Ranbaxy Laboratories Ltd.
www.ranbaxy.com

Regeneron Pharmaceuticals, Inc
www.regeneron.com

RepliGen Corporation
www.repligen.com

Ribozyme Pharmaceuticals, Inc
www.rpi.com

Roche
www.roche.com

Roxane Laboratries, Inc
www.roxane.com

SangStat
www.sangstat.com
(see also Genzyme)

Sanofi-Synthelabo, Inc
www.sanofi-synthelaboUS.com

Salix Pharmaceuticals
www.salixltd.com

Sankyo Co., Ltd.
www.sankyo.co.jp/english/

Schein Pharmaceutical
www.schein-rx.com

Schering-Plough Corporation
www.schering-plough.com

Schwarz Pharma
www.schwarzusa.com

Scios, Inc
www.sciosinc.com

Sepracor, Inc
www.sepracor.com

Serono, Inc
www.seronousa.com

Sheffield Pharmaceuticals
www.sheffieldpharm.com

Shire Pharmaceuticals Group, plc
www.shire.com

SIGA Pharmaceuticals, Inc
www.siga.com

Sigma Tau Pharmaceuticals (US)
www.sigmatau.com

Solvay
www.solvay.com

Sonus Pharmaceuticals
www.sonuspharma.com

SP Pharmaceuticals
www.sppharma.com

Stiefel Laboratories, Inc
www.stiefel.com

SuperGen
www.supergen.com

Synsorb
www.synsorb.com

Takeda Pharmaceuticals America (US)
www.takedapharm.com

TAP Pharmaceuticals
www.tap.com

Taro Pharmaceuticals
www.taropharma.com

Telluride Pharmaceutical Corporation
www.tellpharm.com

Texas Biotechnology Corp. (US)
www.tbc.com

TEVA Pharmaceuticals (US)
www.tevapharmusa.com

Triangle Pharmaceuticals, Inc
www.tripharm.com

UCB
www.ucbpharma.com

Unimed Pharmaceuticals
www.unimed.com

United-Guardian, Inc
www.u-g.com

United Therapeutics
www.unither.com

U.S. Bioscience
www.usbio.com

Wallace Laboratories
www.wallacelabs.com

3880 total views, 3 today

Tools


  • No ads viewed yet.